Timothy Bullock headshot
TB

Timothy N. Bullock

Associate Professor
Unit: School of Medicine
Department: Department of Pathology, Research
Office location and address
345 Crispell Dr
Charlottesville, Virginia 22903
Education
PhD, Thomas Jefferson University
Focused Ultrasound Regimens that Synergize with Melanoma Immunotherapy
Source: U.S. NIH Institute of Biomedical Imaging & Bioengi
July 01, 2020 – March 31, 2024
Enhanced Melanoma Vaccine Against Neoantigens and Shared Antigens by CD40 Activation and TLR Agonists
Source: U.S. DOD - Army - Medical Research Acquisition Act
July 15, 2019 – July 14, 2023
Leveraging MR-guided focused ultrasound to potentiate immunotherapy for GBM
Source: U.S. NIH Cancer Institute
September 19, 2019 – August 31, 2022
MD-PATH Immune Correlate Study of Varlilimumab and Ipilimumab
Source: Celldex Therapeutics, Inc.
May 26, 2015 – May 31, 2022
MD-CANC Cancer Center Support Grant
Source: U.S. NIH Cancer Institute
February 01, 2017 – January 31, 2022
Virginia Kincaid Cancer Research Fund
Source: Virginia Kincaid Charitable Trust
October 01, 2005 – December 31, 2021
Tesaro Study
Source: GlaxoSmithKline LLC
August 10, 2018 – September 18, 2021
In vivo evaluation of the anti-tumor activity of Rb9
Source: Recepta Biopharma S/A
January 15, 2018 – July 15, 2020
EN-BME-MR Immunotherapeutic Nanoparticle Delivery to Melanoma with MR-Guided Focused Ultrasound
Source: U.S. NIH Cancer Institute
June 01, 2015 – May 31, 2020
MD-PATH Functional & Phenotypical Analysis of CDX-1127
Source: Celldex Therapeutics, Inc.
October 01, 2011 – February 01, 2020
MD-PATH Enhancing immune therapy for brain metastases with focused ultrasound
Source: Melanoma Research Alliance
January 01, 2016 – September 30, 2019
MD-PATH Enhancing immune therapy for brain metastases with focused ultrasound - CRI Funding
Source: Cancer Research Institute
January 01, 2016 – July 31, 2019
Development of a Mouse Model for FUS and Breast Cancer
Source: Theraclion, S.A.
May 09, 2016 – May 18, 2018
MD-PATH Assessment of arginase inhibition in NSCLC
Source: Calithera Biosciences, Inc.
May 10, 2016 – May 10, 2018
MD-PATH-BLIMP CD8 TIL Admin (Diversity) Supplementq
Source: U.S. NIH Cancer Institute
January 01, 2013 – December 31, 2017
MD-PATH-BLIMP CD8 TIL Admin (Diversity) Supplement YR04
Source: U.S. NIH Cancer Institute
January 01, 2013 – December 31, 2017
BLIMP-1 mediated regulation of CD8+ TIL
Source: U.S. NIH Cancer Institute
January 01, 2013 – April 05, 2016
Cancer Center Support Grant - Year 21
Source: U.S. NIH Cancer Institute
June 05, 2012 – January 31, 2016
Commonwealth Foundation for Cancer Research
Source: Commonwealth Cancer Foundation for Research
June 01, 2002 – December 31, 2015
Functional proteomics to identify moderators of CD8+ T cell function in melanoma
Source: U.S. DOD - Army - Medical Research Acquisition Act
September 01, 2012 – February 28, 2015
Assessment of melanoma patient lymphocyte responses after CD27 stimulation
Source: Melanoma Research Alliance
September 01, 2011 – August 31, 2013
MD-PATH Understanding the Basis of Sustained vs Transient CD8+ T Cell Responses to Cancer Vaccines
Source: Charles A. Dana Foundation
January 01, 2009 – January 31, 2013
PATH 8300: Tumors and the Immune System
Credits: 2
This module will allow students to gain comprehensive understanding of the extensive interactions between the immune system and neoplasia. The course will focus on discussion of contemporary literature. Students with interests in either cancer biology or immunology are encouraged to register.
PATH 9995: Topical Research
Credits: 1–12
Original research on approved problems.
PATH 9999: Non-Topical Research
Credits: 1–12
Dissertation research credit for students who have completed their advancement to candidacy.